Efficacy Observation of Entecavir Combined with Bifidobacterium Triple Viable Capsules in the Treatment of Patients with Cirrhosis Induced by Chronic Hepatitis B
- VernacularTitle:恩替卡韦联合双歧杆菌三联活菌胶囊治疗慢性乙型肝炎后肝硬化疗效观察
- Author:
Yuli LV
;
Haoyan LU
;
Shudan LI
- Keywords:
Triple viable bifidobacterium capsules;
Entecavir;
Chronic hepatitis B;
Cirrhosis
- From:
China Pharmacist
2017;20(4):677-679
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of entecavir combined with triple viable bifidobacterium capsules in the treatment of patients with cirrhosis induced by chronic hepatitis B.Methods:Totally 86 chronic hepatitis B patients with cirrhosis were randomly divided into the observation group and the control group with 43 ones in each.The control group was given entecavir treatment,and the observation group was treated with triple viable bifidobacterium capsules additionally.The treatment course was three months.The effect of treatment,changes of liver function(TBiL,AST,ALT,etc.),liver fibrosis level (HA,PCⅢ,LN,etc.)and adverse events were compared between the groups before and after the treatment.Results:The total effective rate of the observation group was higher than that of the control group (P<0.05);the levels of TBiL,AST and ALT decreased in both groups after the treatment (P<0.05),and those in the observation group were lower than those in the control group (P<0.05);the levels of HA,PC III and LN decreased in the two groups after the treatment (P<0.05),and those in the observation group were lower than those in the control group (P<0.05);there were no significant adverse drug reactions in both groups during the treatment course.Conclusion:Entecavir combined with triple viable bifidobacterium capsules in the treatment of patients with cirrhosis induced by chronic hepatitis B exhibits significant clinical efficacy,which can improve liver function and liver fibrosis with promising safety and without significant adverse reactions.
